Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The impact of alternate routes of vaccine administration, subcutaneous (SC) or intramuscular (IM), on the safety and immunogenicity of herpes zoster subunit candidate vaccine (HZ/su) was assessed in Japanese adults aged ≥ 50 y. During this phase III open-label study, 60 subjects were randomized (1:1) to receive HZ/su through SC or IM routes in a 0, 2 month schedule. Vaccine response rates (VRRs) and geometric mean concentrations (GMCs) of varicella zoster virus glycoprotein E (gE)-specific antibodies were determined by ELISA. Solicited and unsolicited symptoms were recorded for 7 and 30 d after each vaccination and graded 1-3 in severity. Serious adverse events (SAEs) were recorded throughout the study. At one month post-dose 2, VRRs were 100% (95% Confidence Interval (CI): 88.1-100) in both groups; anti-gE antibody GMCs were 44126.1 mIU/ml (95% CI: 36326.1-53601.0) and 45521.5 mIU/ml (95% CI; 37549.5-55185.9) in the SC and IM groups, respectively. Injection site reactions (pain, swelling and redness) were common, and observed more frequently following SC administration. Grade 3 redness and swelling were more frequently observed after SC administration. Fatigue and headache were the most frequently reported general symptoms for both routes of administration. Ten and 7 unsolicited AEs were reported in the SC and IM group, respectively. Two unsolicited AEs (1 in SC; 1 in IM) were considered related to vaccination by the investigator. Three non-fatal SAEs considered unrelated to vaccination were reported during the study. Administration of the HZ/su vaccine candidate resulted in a substantial immune response that was comparable between SC and IM subjects, but local reactogenicity may be greater for SC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Bacterial and viral infections cause significant morbidity and mortality in persons with DM.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1824]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citationHarpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · PubMed · Cited by 1,037
Herpes Zoster (Shingles) and Postherpetic Neuralgia
Sampathkumar, P., Drage, L. A., & Martin, D. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.274 · Cited by 429
The global epidemiology of herpes zoster
Yawn, B. P., & Gilden, D. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a3516e · Cited by 347
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
Gershon, A. A., Gershon, M. D., Breuer, J., Levin, M. J., Oaklander, A. L., & Griffiths, P. D. (2010) · Journal of Clinical Virology · doi:10.1016/s1386-6532(10)70002-0 · Cited by 313
Similar herpes zoster incidence across Europe: results from a systematic literature review
Pinchinat, S., Cebrián-Cuenca, A. M., Bricout, H., & Johnson, R. W. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-170 · Cited by 245
The importance of injecting vaccines into muscle
Zuckerman, J. N. (2000) · BMJ · doi:10.1136/bmj.321.7271.1237 · Cited by 195
Toyama, N., Shiraki, K., & and Members of the Society of the Miyazaki Prefecture Dermatologists (2009) · Journal of Medical Virology · doi:10.1002/jmv.21599 · Cited by 176
Chlibek, R., Bayas, J. M., Collins, H., de la Pinta, M. L. R., Ledent, E., Mols, J. F., & Heineman, T. C. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit365 · Cited by 149
Self-citation
Research works printed but not linked: 2
- Harpaz R, 2008, MMWR Recomm Rep, 57, 1
- Clark TG, 2005, Dev Biol (Basel), 121, 153
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Vaccines for preventing herpes zoster in older adults
Gagliardi, A. M., Andriolo, B. N., Torloni, M. R., & Soares, B. G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008858.pub3 · Cited by 166
Tricco, A. C., Zarin, W., Cardoso, R., Veroniki, A.-A., Khan, P. A., Nincic, V., Ghassemi, M., Warren, R., Sharpe, J. P., Page, A. V., et al. (2018) · BMJ · doi:10.1136/bmj.k4029 · Cited by 159
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Lecrenier, N., Beukelaers, P., Colindres, R. E., Curran, D., Kesel, C. D., Saegher, J.-P. D., Didierlaurent, A. M., Ledent, E., Mols, J., Mrkvan, T., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1495565 · Cited by 119
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Syed, Y. Y. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0603-x · Cited by 111
Metadata
- Authors
- Vink, P., Shiramoto, M., Ogawa, M., Eda, M., Douha, M., Heineman, T., & Lal, H.
- Affiliations
- GlaxoSmithKline (United States) (US)
- SOUSEKAI PS Clinic, Tenyamachi, Hakata-ku, Fukuoka, Japan
- Japan Vaccine Company Ltd., Chiyoda-ku, Tokyo, Japan
- GlaxoSmithKline (Belgium) (BE)
- Corresponding author
- Vink, Peter
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2016-12-09
- Volume
- 13
- Issue
- 3
- Pages
- 574-578
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC5360149
- OpenAlex
- W2561886913
- Cited by
- 26
- References
- 27
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 6 · 2018: 7 · 2017: 1 · 2016: 1
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Keywords
- varicella-zoster virus, vaccine route of administration, subcutaneous injection, intramuscular injection, immunogenicity, vaccine safety, injection site reactions, older adults, Japanese population
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Female, Humans, Injections, Intramuscular, Injections, Subcutaneous, Japan, Male, Middle Aged, Viral Envelope Proteins, Vaccines, Subunit, Herpes Zoster Vaccine, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. https://app.cochat.ai/papers/10.1080/21645515.2016.1232787
- The paper
- Vink, P., Shiramoto, M., Ogawa, M., Eda, M., Douha, M., Heineman, T., & Lal, H. (2017). Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2016.1232787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.